In colorectal cancer, most biological drugs that are used target the epidermal growth factor receptor (EGFR), which mediates cellular response to growth signals and is known to be over-expressed in 50–80% of colorectal tumors [2,3,4]. The gene discussed is EGFR; the disease is colorectal neoplasm.